Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice
-
- Michihiro Mieda
- Department of Molecular Genetics and Howard Hughes Medical Institute, and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-9050; Department of Pharmacology, Institute of Basic Medical Sciences, University of Tsukuba, Ibaraki 305-8575, Japan; and Exploratory Research for Advanced Technology, Yanagisawa Orphan Receptor Project, Japan Science and Technology Agency, Tokyo 135-0064, Japan
-
- Jon T. Willie
- Department of Molecular Genetics and Howard Hughes Medical Institute, and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-9050; Department of Pharmacology, Institute of Basic Medical Sciences, University of Tsukuba, Ibaraki 305-8575, Japan; and Exploratory Research for Advanced Technology, Yanagisawa Orphan Receptor Project, Japan Science and Technology Agency, Tokyo 135-0064, Japan
-
- Junko Hara
- Department of Molecular Genetics and Howard Hughes Medical Institute, and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-9050; Department of Pharmacology, Institute of Basic Medical Sciences, University of Tsukuba, Ibaraki 305-8575, Japan; and Exploratory Research for Advanced Technology, Yanagisawa Orphan Receptor Project, Japan Science and Technology Agency, Tokyo 135-0064, Japan
-
- Christopher M. Sinton
- Department of Molecular Genetics and Howard Hughes Medical Institute, and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-9050; Department of Pharmacology, Institute of Basic Medical Sciences, University of Tsukuba, Ibaraki 305-8575, Japan; and Exploratory Research for Advanced Technology, Yanagisawa Orphan Receptor Project, Japan Science and Technology Agency, Tokyo 135-0064, Japan
-
- Takeshi Sakurai
- Department of Molecular Genetics and Howard Hughes Medical Institute, and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-9050; Department of Pharmacology, Institute of Basic Medical Sciences, University of Tsukuba, Ibaraki 305-8575, Japan; and Exploratory Research for Advanced Technology, Yanagisawa Orphan Receptor Project, Japan Science and Technology Agency, Tokyo 135-0064, Japan
-
- Masashi Yanagisawa
- Department of Molecular Genetics and Howard Hughes Medical Institute, and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-9050; Department of Pharmacology, Institute of Basic Medical Sciences, University of Tsukuba, Ibaraki 305-8575, Japan; and Exploratory Research for Advanced Technology, Yanagisawa Orphan Receptor Project, Japan Science and Technology Agency, Tokyo 135-0064, Japan
抄録
<jats:p> Narcolepsy-cataplexy is a neurological disorder associated with the inability to maintain wakefulness and abnormal intrusions of rapid eye movement sleep-related phenomena into wakefulness such as cataplexy. The vast majority of narcoleptic-cataplectic individuals have low or undetectable levels of orexin (hypocretin) neuropeptides in the cerebrospinal fluid, likely due to specific loss of the hypothalamic orexin-producing neurons. Currently available treatments for narcolepsy are only palliative, symptom-oriented pharmacotherapies. Here, we demonstrate rescue of the narcolepsy-cataplexy phenotype of orexin neuron-ablated mice by genetic and pharmacological means. Ectopic expression of a <jats:italic>prepro-orexin</jats:italic> transgene in the brain completely prevented cataplectic arrests and other abnormalities of rapid eye movement sleep in the absence of endogenous orexin neurons. Central administration of orexin-A acutely suppressed cataplectic behavioral arrests and increased wakefulness for 3 h. These results indicate that orexin neuron-ablated mice retain the ability to respond to orexin neuropeptides and that a temporally regulated and spatially targeted secretion of orexins is not necessary to prevent narcoleptic symptoms. Orexin receptor agonists would be of potential value for treating human narcolepsy. </jats:p>
収録刊行物
-
- Proceedings of the National Academy of Sciences
-
Proceedings of the National Academy of Sciences 101 (13), 4649-4654, 2004-03-16
Proceedings of the National Academy of Sciences
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1363107370153405312
-
- NII論文ID
- 30016240271
-
- ISSN
- 10916490
- 00278424
-
- データソース種別
-
- Crossref
- CiNii Articles